GlaxoSmithKline submits new diabetes drug for US approval

14th Jan 2013 10:38

Pharma giant GlaxoSmithKline (GSK) submitted its latest treatment for type two diabetes to the US Food and Drug Administration (FDA) for regulatory approval.The firm said albiglutide BLA, an investigational once-weekly treatment for adult patients, was not yet approved as a treatment for type two diabetes or any other indication anywhere in the world. GSK intends to submit a regulatory application in the European Union in early 2013.At 1030 the company's share were down 0.65% at 1,373.5p.MM